The global market for Glucagon was estimated at US$434.2 Million in 2024 and is projected to reach US$547.2 Million by 2030, growing at a CAGR of 3.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Glucagon market.
Recent advancements in glucagon formulations, including auto-injectors, nasal sprays, and long-acting analogs, have improved patient accessibility and ease of administration. These innovations have enhanced emergency hypoglycemia management, particularly for individuals who struggle with injectable treatments. Additionally, pharmaceutical companies are exploring novel applications for glucagon in metabolic disease modulation, including appetite regulation and energy balance, further expanding its therapeutic potential. As research continues to uncover new uses for glucagon, its role in modern medicine is becoming increasingly indispensable.
In diagnostic imaging, glucagon is used as a smooth muscle relaxant to improve the visualization of the gastrointestinal tract during radiological procedures such as MRI and CT scans. Its ability to temporarily reduce peristalsis makes it valuable for obtaining high-quality images of the stomach and intestines. Additionally, ongoing research is investigating glucagon’s potential in obesity management, as it has been shown to suppress appetite and increase energy expenditure. With expanding applications in metabolic disease treatment and medical imaging, the demand for glucagon continues to rise across multiple healthcare sectors.
Additionally, pharmaceutical companies are developing long-acting glucagon analogs designed for continuous glucose modulation in metabolic disorders. AI-driven drug discovery and peptide engineering techniques have enabled the optimization of glucagon analogs with improved pharmacokinetics, making them more suitable for long-term treatment applications. Furthermore, research into dual and triple hormone therapies combining glucagon with GLP-1 receptor agonists is gaining traction for treating obesity and type 2 diabetes. These advancements are positioning glucagon as a multi-functional hormone with significant therapeutic potential beyond emergency hypoglycemia management.
Additionally, the expansion of glucagon’s role in diagnostic imaging and metabolic disease treatment has created new market opportunities. Regulatory approvals for novel formulations and combination therapies are further accelerating industry growth. Pharmaceutical companies investing in peptide engineering and next-generation glucagon analogs are driving innovation, positioning glucagon as a key player in future metabolic therapies. As demand for effective, versatile hormone-based treatments continues to rise, the glucagon market is expected to experience strong and sustained growth.
Segments: Product (Injectable Glucagon, Inhalation Glucagon); Application (Hypoglycemia Application, Diagnostic Aid Application, Gastrointestinal Disorders Application, Cardiogenic Shock Application, Other Applications); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Glucagon Market - Key Trends & Drivers Summarized
Why Is Glucagon a Critical Hormone in Metabolic and Emergency Medicine?
Glucagon, a peptide hormone produced by the pancreas, plays a vital role in glucose metabolism by stimulating the liver to release stored glucose, thereby increasing blood sugar levels. Traditionally known for its role in managing severe hypoglycemia in diabetic patients, glucagon has expanded its clinical applications beyond diabetes treatment. It is now being used in diagnostic imaging, gastrointestinal procedures, and even as a potential therapy for obesity and metabolic disorders. The growing prevalence of diabetes and the need for fast-acting, reliable treatments for hypoglycemic episodes have significantly boosted demand for glucagon-based therapies.Recent advancements in glucagon formulations, including auto-injectors, nasal sprays, and long-acting analogs, have improved patient accessibility and ease of administration. These innovations have enhanced emergency hypoglycemia management, particularly for individuals who struggle with injectable treatments. Additionally, pharmaceutical companies are exploring novel applications for glucagon in metabolic disease modulation, including appetite regulation and energy balance, further expanding its therapeutic potential. As research continues to uncover new uses for glucagon, its role in modern medicine is becoming increasingly indispensable.
Which Medical Applications Are Driving Demand for Glucagon?
The primary use of glucagon remains in emergency medicine for the treatment of severe hypoglycemia in patients with type 1 and type 2 diabetes. Traditional glucagon injections and newer intranasal formulations are widely used by caregivers and healthcare providers to rapidly restore blood glucose levels in unconscious or severely hypoglycemic patients. However, recent advancements have expanded glucagon’s use into new therapeutic areas, including diagnostic imaging and gastrointestinal (GI) procedures.In diagnostic imaging, glucagon is used as a smooth muscle relaxant to improve the visualization of the gastrointestinal tract during radiological procedures such as MRI and CT scans. Its ability to temporarily reduce peristalsis makes it valuable for obtaining high-quality images of the stomach and intestines. Additionally, ongoing research is investigating glucagon’s potential in obesity management, as it has been shown to suppress appetite and increase energy expenditure. With expanding applications in metabolic disease treatment and medical imaging, the demand for glucagon continues to rise across multiple healthcare sectors.
What Are the Latest Technological Innovations in Glucagon Drug Development?
Recent innovations in glucagon drug development have focused on improving formulation stability, ease of administration, and therapeutic efficacy. One of the most significant advancements is the introduction of ready-to-use auto-injectors and nasal spray formulations, which eliminate the need for reconstitution and improve emergency response times. These user-friendly delivery systems have increased glucagon adoption, particularly in home settings where rapid intervention is necessary.Additionally, pharmaceutical companies are developing long-acting glucagon analogs designed for continuous glucose modulation in metabolic disorders. AI-driven drug discovery and peptide engineering techniques have enabled the optimization of glucagon analogs with improved pharmacokinetics, making them more suitable for long-term treatment applications. Furthermore, research into dual and triple hormone therapies combining glucagon with GLP-1 receptor agonists is gaining traction for treating obesity and type 2 diabetes. These advancements are positioning glucagon as a multi-functional hormone with significant therapeutic potential beyond emergency hypoglycemia management.
What Factors Are Fueling the Growth of the Glucagon Market?
The growth in the glucagon market is driven by several factors, including the rising incidence of diabetes, increasing awareness of hypoglycemia management, and expanding therapeutic applications. The growing diabetic population worldwide has heightened the demand for emergency glucagon treatments, particularly in home-use settings where caregivers require user-friendly solutions. The introduction of nasal and auto-injector formulations has further boosted adoption rates by improving ease of use.Additionally, the expansion of glucagon’s role in diagnostic imaging and metabolic disease treatment has created new market opportunities. Regulatory approvals for novel formulations and combination therapies are further accelerating industry growth. Pharmaceutical companies investing in peptide engineering and next-generation glucagon analogs are driving innovation, positioning glucagon as a key player in future metabolic therapies. As demand for effective, versatile hormone-based treatments continues to rise, the glucagon market is expected to experience strong and sustained growth.
Report Scope
The report analyzes the Glucagon market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Product (Injectable Glucagon, Inhalation Glucagon); Application (Hypoglycemia Application, Diagnostic Aid Application, Gastrointestinal Disorders Application, Cardiogenic Shock Application, Other Applications); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Injectable Glucagon segment, which is expected to reach US$353.9 Million by 2030 with a CAGR of a 3.3%. The Inhalation Glucagon segment is also set to grow at 5.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $118.3 Million in 2024, and China, forecasted to grow at an impressive 7.1% CAGR to reach $110.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Glucagon Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Glucagon Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Glucagon Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Amphastar Pharmaceuticals, Inc., Arecor Therapeutics plc, Aurobindo Pharma Limited, Avalon Pharma Private Limited, Bachem AG and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 32 Featured):
- Amphastar Pharmaceuticals, Inc.
- Arecor Therapeutics plc
- Aurobindo Pharma Limited
- Avalon Pharma Private Limited
- Bachem AG
- Bachem Holding AG
- Eli Lilly and Company
- Fresenius SE & Co. KGaA
- Fujifilm Holdings Corporation
- Hybio Pharmaceutical
- ILS Inc.
- Jin Dun Medical
- Novo Nordisk A/S
- Pfizer Inc.
- Piramal Pharma Solutions
- Svar Life Science
- Taj Pharmaceuticals Limited
- United Biotech (P) Limited
- Xeris Biopharma Holdings, Inc.
- Zealand Pharma A/S
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amphastar Pharmaceuticals, Inc.
- Arecor Therapeutics plc
- Aurobindo Pharma Limited
- Avalon Pharma Private Limited
- Bachem AG
- Bachem Holding AG
- Eli Lilly and Company
- Fresenius SE & Co. KGaA
- Fujifilm Holdings Corporation
- Hybio Pharmaceutical
- ILS Inc.
- Jin Dun Medical
- Novo Nordisk A/S
- Pfizer Inc.
- Piramal Pharma Solutions
- Svar Life Science
- Taj Pharmaceuticals Limited
- United Biotech (P) Limited
- Xeris Biopharma Holdings, Inc.
- Zealand Pharma A/S
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 368 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 434.2 Million |
| Forecasted Market Value ( USD | $ 547.2 Million |
| Compound Annual Growth Rate | 3.9% |
| Regions Covered | Global |
